Targeted Therapy and Immunotherapy in the Treatment of Non-Small Cell Lung Cancer.

Related Articles

Targeted Therapy and Immunotherapy in the Treatment of Non-Small Cell Lung Cancer.

Radiol Clin North Am. 2018 May;56(3):485-495

Authors: Shroff GS, de Groot PM, Papadimitrakopoulou VA, Truong MT, Carter BW

Abstract
The treatment strategy in advanced non-small cell lung cancer (NSCLC) has evolved from empirical chemotherapy to a personalized approach based on histology and molecular markers of primary tumors. Targeted therapies are directed at the products of oncogenic driver mutations. Immunotherapy facilitates the recognition of cancer as foreign by the host immune system, stimulates the immune system, and alleviates the inhibition that allows the growth and spread of cancer cells. The authors describes the role of targeted therapy and immunotherapy in the treatment of NSCLC, patterns of disease present on imaging studies, and immune-related adverse events encountered with immunotherapy.

PMID: 29622080 [PubMed - indexed for MEDLINE]

https://ift.tt/2HfXjFK